United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable
439 Views19 Sep 2023 12:21
United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have different challenges. The Placing is not attractive.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Beijing Yuanxin Technology Group - Some Points Worth the Attention26 Sep 2023
- China Healthcare Weekly (Sep.22) - Medical Device VBP, Restore Optimism on Healthcare, Biokin Pharma24 Sep 2023
- BeiGene (6160.HK/BGNE.US) - The Truth Behind Novartis' Divorce Decision on PD-121 Sep 2023
- United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable19 Sep 2023
- Chunlizhengda Medical Instruments (1858.HK/688236.CH) - 2023 Full-Year Results May Be Disappointing19 Sep 2023
- Turnaround in China Healthcare Anti-Corruption: Impact on Company’s 2023 Results & Upcoming New Reforms18 Sep 2023
- Innovent Biologics Placement (1801.HK) - There Is No Such Thing as a Free Lunch12 Sep 2023
x